- VernacularTitle: 质子重离子肿瘤放疗的临床注册试验初步报告
- Author:
Jiade LU
1
;
Ming YE
2
;
Xiaomao GUO
1
,
3
;
Shen FU
1
,
3
;
F. Michael MOYERS
4
;
Qing ZHANG
1
;
Jingfang MAO
1
,
3
;
Lin KONG
1
,
3
;
Wen Chien HSI
4
;
Kambiz SHAHNAZI
4
;
Jingfang ZHAO
3
,
4
;
Zhen ZHANG
1
,
3
;
Xiumei MA
2
;
Songtao LAI
5
;
Xiaomeng ZHANG
1
,
3
;
Ningyi MA
1
;
Yunsheng GAO
6
;
Xin CAI
1
;
Xiyin GUAN
1
;
Junhua ZHANG
5
;
Bin WU
7
,
8
;
Jingyi CHENG
9
,
10
;
Yin-xiang-zi SHENG
4
;
Wei REN
4
;
Jun ZHAO
3
,
4
;
Lining SUN
3
,
4
;
Guoliang JIANG
1
,
3
Author Information
- Publication Type:Clinical Trail
- Keywords: Neoplasms; Proton; Carbon ion; Radiotherapy; Clinical trial
- From: Chinese Journal of Oncology 2018;40(1):52-56
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To verify the safety and efficacy of IONTRIS particle therapy system (IONTRIS) in clinical implementation.
Methods:Between 6.2014 and 8.2014, a total of 35 patients were enrolled into this trial: 31 males and 4 females with a median age of 69 yrs (range 39-80). Ten patients had locally recurrent head and neck tumors after surgery, 4 cases with thoracic malignancies, 1 case with hepatocellular carcinoma, 1 case with retroperitoneal sarcoma, and 19 cases with non-metastatic prostate carcinomas. Phantom dose verification was mandatory for each field before the start of radiation.
Results:Twenty-two patients received carbon ion and 13 had proton irradiation. With a median follow-up time of 1 year, all patients were alive. Among the 16 patients with head and neck, thoracic, and abdominal/pelvic tumors, 2, 1, 12, and 1 cases developed complete response, partial response, stable disease, or disease progression, respectively. Progression-free survival rate was 93.8% (15/16). Among the 19 patients with prostate cancer, biological-recurrence free survival was 100%. Particle therapy was well tolerated in all 35 patients. Twenty-five patients (71.4%) experienced 33 grade 1 acute adverse effects, which subsided at 1 year follow-up. Six (17.1%) patients developed grade 1 late adverse effects. No significant change in ECOG or body weight was observed.
Conclusions:IONTRIS is safe and effective for clinical use. However, long term follow-up is needed to observe the late toxicity and long term result.